168 related articles for article (PubMed ID: 15507296)
1. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort.
Petri M
Thromb Res; 2004; 114(5-6):593-5. PubMed ID: 15507296
[TBL] [Abstract][Full Text] [Related]
2. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
[TBL] [Abstract][Full Text] [Related]
3. [Antiphospholipid syndrome and stroke].
Kitagawa Y
Rinsho Shinkeigaku; 2005 Nov; 45(11):852-5. PubMed ID: 16447744
[TBL] [Abstract][Full Text] [Related]
4. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
Somers E; Magder LS; Petri M
J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
[TBL] [Abstract][Full Text] [Related]
5. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort.
Petri M
Lupus; 2010 Apr; 19(4):419-23. PubMed ID: 20353980
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.
Vayá A; Santaolaria M; Micó L; Calvo J; Oropesa R; Villa P; Todoli J; Simó M; Corella D; Ricart JM
Clin Hemorheol Microcirc; 2008; 40(2):79-87. PubMed ID: 19029633
[TBL] [Abstract][Full Text] [Related]
7. Significance of antiphospholipid antibodies in lupus nephritis.
Natejumnong C; Ruangkanchanasetr P; Aimpun P; Supaporn T
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S121-8. PubMed ID: 17044463
[TBL] [Abstract][Full Text] [Related]
8. Antiphospholipid antibody tests: spreading the net.
Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid antibodies in young myocardial infarction patients.
Mishra MN; Kalra R; Gupta MK
Indian J Biochem Biophys; 2007 Dec; 44(6):481-4. PubMed ID: 18320848
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura.
Pierrot-Deseilligny Despujol C; Michel M; Khellaf M; Gouault M; Intrator L; Bierling P; Godeau B
Br J Haematol; 2008 Aug; 142(4):638-43. PubMed ID: 18510681
[TBL] [Abstract][Full Text] [Related]
11. [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome].
Reshetniak TM; Seredavkina nV; Mach ES; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
Ter Arkh; 2008; 80(10):60-7. PubMed ID: 19105418
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus.
Kiani A; Mahoney JA; Petri M
J Rheumatol; 2007 May; 34(5):969-72. PubMed ID: 17407217
[TBL] [Abstract][Full Text] [Related]
13. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
[TBL] [Abstract][Full Text] [Related]
14. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
15. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
[TBL] [Abstract][Full Text] [Related]
16. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity.
Kiani AN; Magder L; Petri M
J Rheumatol; 2008 Jul; 35(7):1300-6. PubMed ID: 18484694
[TBL] [Abstract][Full Text] [Related]
17. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.
Farzaneh-Far A; Roman MJ; Lockshin MD; Devereux RB; Paget SA; Crow MK; Davis A; Sammaritano L; Levine DM; Salmon JE
Arthritis Rheum; 2006 Dec; 54(12):3918-25. PubMed ID: 17133599
[TBL] [Abstract][Full Text] [Related]
18. The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation.
Aboud MR; Roddie C; Ward CM; Coyle L
Clin Lab Haematol; 2006 Apr; 28(2):105-10. PubMed ID: 16630214
[TBL] [Abstract][Full Text] [Related]
19. Antiphospholipid (aPL) antibodies in end-stage renal disease.
Fabrizi F; Sangiorgio R; Pontoriero G; Corti M; Tentori F; Troina E; Locatelli F
J Nephrol; 1999; 12(2):89-94. PubMed ID: 10378664
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
